Physician

Marays Veliz, MD

According to 2025 Medicare claims, Marays Veliz, MD (NPI: 1023213089) practices internal medicine in the Orlando-Kissimmee-Sanford, FL market, with the plurality of this provider's patient population coming from Lake, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32159-8984.

Veliz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,152 traditional Medicare patients, billed 245,823 HCPCS/CPT codes, and received $2,742,687 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 1,448 prescription claims across 308 beneficiaries totaling $2,852,475 in drug costs, led by Revlimid (Lenalidomide). 2022 DME data shows 29 claims. Open Payments data shows 78 records totaling $1,679. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have moved sharply higher in recent years, from $896,902 to $2,852,475. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,287 to $1,414.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,093	379,276	$2,443,464
2016	1,249	310,851	$2,743,038
2017	1,573	311,507	$3,108,356
2018	1,481	308,068	$3,740,238
2019	1,456	324,563	$4,038,398
2020	1,248	295,305	$3,422,396
2021	1,188	260,407	$3,199,780
2022	988	254,939	$3,198,930
2023	1,079	208,026	$2,659,183
2024	1,152	245,823	$2,742,687

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	185	1,239	$896,902
2016	194	1,001	$629,540
2017	230	1,186	$1,038,189
2018	278	1,262	$994,366
2019	295	1,450	$1,069,156
2020	265	1,439	$1,723,995
2021	281	1,389	$2,744,196
2022	291	1,321	$2,361,308
2023	295	1,417	$2,690,718
2024	308	1,448	$2,852,475

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	65	$5,778
2016	N/R	35	$1,278
2017	N/R	42	$16,385
2018	N/R	N/R	N/R
2019	N/R	N/R	N/R
2020	N/R	41	$5,274
2021	N/R	N/R	N/R
2022	N/R	29	$1,384
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	267	531	$93
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	349	591	$65
96372	Injection of drug or substance under skin or into muscle	267	1,003	$10
36415	Insertion of needle into vein for collection of blood sample	707	1,863	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	678	1,869	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	40	1,085	$681,608
Brukinsa	Zanubrutinib	33	990	$470,289
Calquence	Acalabrutinib Maleate	11	330	$169,396
Eliquis	Apixaban	143	8,730	$167,513
Gleevec	Imatinib Mesylate	12	360	$115,882

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	78	$1,679	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Marays Veliz, MD?

Tedicare shows public-source Medicare data for Marays Veliz, MD (NPI 1023213089), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Marays Veliz, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Marays Veliz, MD?

Marays Veliz, MD is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Marays Veliz, MD have Open Payments data?

Marays Veliz, MD has 78 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.